Drug General Information
Drug ID
D0R7IM
Former ID
DIB021123
Drug Name
UFP-101
Synonyms
[Nphe1,Arg14,Lys15]N/OFQ-NH2; UFP101; [Nphe1,Arg14,Lys15]nociceptin-NH2; UFP 101
Drug Type
Small molecular drug
Indication Discovery agent Investigative [539049]
Structure
Download
2D MOL
Formula
C73H124N28O17
InChI
InChI=1S/C73H124N28O17/c1-42(91-57(106)40-90-70(118)59(44(3)103)101-68(116)53(35-45-19-6-4-7-20-45)93-58(107)39-89-56(105)38-88-55(104)37-84-36-46-21-8-5-9-22-46)61(109)95-50(26-16-32-85-71(78)79)65(113)98-49(25-12-15-31-76)67(115)100-54(41-102)69(117)92-43(2)62(110)96-51(27-17-33-86-72(80)81)66(114)97-48(24-11-14-30-75)64(112)99-52(28-18-34-87-73(82)83)63(111)94-47(60(77)108)23-10-13-29-74/h4-9,19-22,42-44,47-54,59,84,102-103H,10-18,23-41,74-76H2,1-3H3,(H2,77,108)(H,88,104)(H,89,105)(H,90,118)(H,91,106)(H,92,117)(H,93,107)(H,94,111)(H,95,109)(H,96,110)(H,97,114)(H,98,113)(H,99,112)(H,100,115)(H,101,116)(H4,78,79,85)(H4,80,81,86)(H4,82,83,87)/t42-,43-,44+,47-,48-,49-,50-,51-,52-,53-,54-,59-/m0/s1
InChIKey
JEXLNFNIIVBCHM-OSMJMQRHSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Nociceptin receptor Target Info Antagonist [526331]
KEGG Pathway Neuroactive ligand-receptor interaction
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Reactome Peptide ligand-binding receptors
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 539049(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1694).
Ref 526331Nphe1,Arg14,Lys15nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol. 2002 May;136(2):303-11.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.